An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.
Status:
Not yet recruiting
Trial end date:
2025-07-22
Target enrollment:
Participant gender:
Summary
Following an infection with Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV2), one
in ten people will experience persisting symptoms, or develop symptoms which can last for
months and even years. These symptoms affect people in different ways and have been
demonstrated to broadly impact physical, mental, and cognitive health. This is called Long
COVID. Currently, there are no treatments available to address the issues that patients
experience but anti-viral medications have been suggested as being potentially effective.
This study will recruit patients that have confirmed long COVID and participants will
undertake a series of tests to determine their symptoms and the impact that their condition
has had on their bodily systems. The total duration of each participant's involvement is
approximately 8 weeks, and this will involve 13 visits (15 visits if taking part in Exeter)
at the closest study location (Derby or Exeter). Initial assessments are conducted over three
separate visits and then all participants will be scheduled to receive five consecutive days
of a medication that has been identified as having the potential to reduce the impact of Long
COVID. Following a period of 28 days, participants will be invited to repeat the same tests
that were conducted before receiving the medication so that it can be determined how well the
drug has worked. In this study we are specifically collecting information to understand how
feasible this medication could be to help patients improve their condition and this will help
us to determine how likely this drug is able to be used within the wider Long COVID
community.
The medication that will be used within this study is an existing anti-viral medication
(Remdesivir). If we find patients are able to tolerate the treatment and the research tasks
we will use this information to conduct a larger trial to determine how well this drug can be
used to reduce the impact of Long COVID in a greater number of patients.
Phase:
Phase 4
Details
Lead Sponsor:
University of Derby
Collaborators:
Peninsula Clinical Trials Unit University Hospitals of Derby and Burton NHS Foundation Trust University of Exeter